Reclassification of marijuana opens doors for much-needed medical research … – The Conversation
The DEA's proposed reclassification of cannabis from Schedule I to Schedule III represents a watershed moment for medical research opportunities in cannabis medicine. This regulatory shift will remove decades-old barriers to rigorous clinical studies…
Characterizing public comments via Regulations.gov in response to proposed cannabis rescheduling in the United States.
The United States Drug Enforcement Administration's (DEA) proposed rescheduling of cannabis from Schedule I to Schedule III under the Controlled Substances A...
Bring It On: Meet the Cannabis CMO Welcoming Scrutiny With Open Arms
The cannabis clinical scrutiny embraced by industry leaders marks a pivotal shift toward transparency and patient safety. This approach ensures clinicians have reliable data for evidence-based prescribing decisions. Cannabis clinical scrutiny benefits…
Impact of Medicinal Cannabis Crackdowns on Sales and Patient Access
Medicinal cannabis crackdowns have led to notable declines in sales, reflecting access barriers and regulatory challenges. Understanding these market dynamics is essential for clinicians to anticipate patient care impacts. This analysis of medicinal…
Hemp Businesses in Massachusetts Face Uncertain Future Amid Federal Ban
Federal hemp regulatory uncertainty is creating challenges for Massachusetts hemp businesses and patient access to cannabinoid therapies. The looming federal ban on intoxicating hemp compounds complicates clinical prescribing and treatment continuity.…
Regulating Payment of Participant Data in Clinical Trials | The Regulatory Review
Regulating payment participant data clinical trials is crucial for ensuring ethical standards and scientific integrity. This article discusses how payment structures impact cannabis clinical trials. Understanding these regulations helps improve…
CCB Deputy Director Miles Named Acting Executive Director
Cannabis regulatory oversight continuity is critical as Nevada appoints Deputy Director Miles as Acting Executive Director. This leadership change supports stable medical cannabis program operations. Patients and clinicians can expect consistent…
Regulatory Digest: DEA Enforcement & Controlled Substances March 2026
This regulatory digest covers DEA enforcement controlled substances updates relevant to cannabis and synthetic cannabinoid importation. The March 2026 notices highlight scheduling changes and import restrictions. Clinicians should stay informed about…